Evidence map›Paper›PMID 40869345›Full record

ReviewInternational journal of molecular sciences2025

Nanomaterials in COPD: Emerging Therapeutic and Diagnostic Frontiers with a Focus on Metal-Organic Frameworks.

Antonio Tiralosi, Manuela Cambria, Mariachiara Campanella, Vincenzo Paratore, Cristina Russo, Lucia Malaguarnera, Maria Stella Valle, Maria Teresa Cambria

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Antonio TiralosiVolunteers Organization, Via re Martino 84a, 95126 Catania, Italy.ORCID 0009-0004-6758-962X
Manuela CambriaVolunteers Organization, Via re Martino 84a, 95126 Catania, Italy.
Mariachiara CampanellaSection of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Vincenzo ParatoreDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID 0009-0004-7095-1984
Cristina RussoSection of Pathology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-6709-4537
Lucia MalaguarneraSection of Pathology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-5171-7963
Maria Stella ValleSection of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-9728-3542
Maria Teresa CambriaSection of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-7541-656X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. Although conventional therapies are effective in controlling symptoms, they remain limited in altering the course of the disease and significantly reducing the chronic inflammation and oxidative stress underlying it. In this context, nanoparticles and nanomaterials are emerging as innovative tools capable of overcoming traditional pharmacological barriers due to their ability to deliver therapeutic oligonucleotides, antioxidants, and drugs in a targeted manner, modulate immune responses, and improve the bioavailability of active compounds. In particular, metal-organic frameworks (MOFs) stand out as ideal candidates for inhalable drug delivery in COPD, owing to their permanent crystalline porous structure, high specific surface area, and versatile chemical functionalization. This review provides the most recent preclinical evidence on the use of different nanoparticles in COPD, with a focus on the therapeutic and diagnostic potential of MOFs. It discusses their biocompatibility, drug loading strategies, and controlled release mechanisms and explores future perspectives for clinical translation.

Indexed as

Metal-Organic FrameworksNanostructuresPulmonary Disease, Chronic ObstructiveAnimalsDrug Delivery SystemsHumansMetal-Organic Frameworksalveolar targetingchronic obstructive pulmonary diseaseinhalable drug deliveryMOFsnanomaterials

Identifiers

PMID40869345
PMCPMC12386663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.